Actively Recruiting
Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
Led by Innovaderm Research Inc. · Updated on 2025-03-24
20
Participants Needed
2
Research Sites
97 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a single-blind, intraindividual study to evaluate the efficacy of ruxolitinib 1.5 % cream in adult subjects with discoid lupus erythematosus.
CONDITIONS
Official Title
Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female subject 18 years of age or older at the time of consent.
- Confirmed DLE diagnosis.
- Subject has moderate to severe DLE, as defined by an overall CLA IGA score of 3 (moderate) or 4 (severe) at screening and Day 1.
- Female subject of childbearing potential must have a negative urine pregnancy test at screening and negative urine pregnancy test at Day 1.
- Subject has no known history of latent or active tuberculosis (TB) infection.
- Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures.
- Subjects must be willing to comply with all study procedures and must be available for the duration of the study.
You will not qualify if you...
- Female subject who is breastfeeding, pregnant, or who is planning to become pregnant during the study.
- Subject has a history of skin disease or presence of skin condition that would interfere with the study assessments.
- Subject has unstable or fluctuating use of nicotine-containing products within 4 weeks prior to screening.
- Subject is known to have immune deficiency or is immunocompromised.
- Subject is 60; 50 years old AND has a history of heart attack, other clinically significant heart problems, stroke, or blood clots.
- Subject has a known history of chronic infectious disease (e.g., hepatitis B, hepatitis C, or human immunodeficiency virus [HIV]).
- Subject is known to have hepatitis B or hepatitis C viral infection.
- Subject has used any topical medicated treatment that could affect DLE within 2 weeks prior to Day 1, including, but not limited to, topical corticosteroids, retinoids, calcineurin inhibitors, antimicrobials, and medical devices.
- Subject has received any marketed or investigational biological agent within 12 weeks or 5 half lives (whichever is longer) prior to Day 1, including but not limited to ustekinumab and rituximab.
- Subject is currently receiving a nonbiological investigational product or device or has received one within 4 weeks prior to Day 1.
- Subject has a known or suspected allergy to ruxolitinib.
- Subject has used ruxolitinib cream (OpzeluraTM).
- Subject has used JAK inhibitors for conditions other than DLE or other forms of lupus within 4 weeks prior to Day 1.
- Subject has a known history of clinically significant drug or alcohol abuse in the last year prior to Day 1.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
INNO-6051 Site 03
Fredericton, New Brunswick, Canada, E3B 1G9
Actively Recruiting
2
Innovaderm Research Inc.
Montreal, Quebec, Canada, H2X 2V1
Actively Recruiting
Research Team
F
Fareheen Chowdhury
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here